Coagulant Patents (Class 514/834)
-
Patent number: 8859526Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.Type: GrantFiled: September 29, 2010Date of Patent: October 14, 2014Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventor: Kirk W. Johnson
-
Patent number: 8771973Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.Type: GrantFiled: May 19, 2011Date of Patent: July 8, 2014Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventor: Kirk W. Johnson
-
Patent number: 8765665Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: February 6, 2013Date of Patent: July 1, 2014Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 8435792Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.Type: GrantFiled: May 19, 2011Date of Patent: May 7, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
-
Patent number: 8372800Abstract: An albumin-free Factor VIII formulation comprising: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.Type: GrantFiled: September 30, 2011Date of Patent: February 12, 2013Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 8362081Abstract: A method of treating a hemorrhagic condition in a subject in need thereof, comprising administering a composition comprising a therapeutically effective amount of Dencichine, a co-solvent, a dispersion supporter, and optionally a cryoprotectant. Compositions and formulations comprising a solid dispersion composition of Dencichine and methods for preparation of same are also described.Type: GrantFiled: December 31, 2009Date of Patent: January 29, 2013Inventors: Guihua Lan, Ping Chen, Qiu Sun, Song Fang
-
Patent number: 8058226Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: June 18, 2007Date of Patent: November 15, 2011Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 7829549Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.Type: GrantFiled: April 13, 2009Date of Patent: November 9, 2010Assignees: Baxter International Inc., Baxter Healthcare S. A.Inventor: Kirk W. Johnson
-
Patent number: 7291333Abstract: A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma.Type: GrantFiled: October 14, 1994Date of Patent: November 6, 2007Assignee: Oklahoma Medical Research FoundationInventor: Philip C. Comp
-
Patent number: 7271143Abstract: Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators.Type: GrantFiled: March 12, 2003Date of Patent: September 18, 2007Assignee: Thrombotech Ltd.Inventor: Abd. Al-Roof Higazi
-
Patent number: 7268110Abstract: Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.Type: GrantFiled: April 21, 2005Date of Patent: September 11, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masahiko Tamura, Yasuhiro Oda
-
Patent number: 7247707Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: May 15, 2006Date of Patent: July 24, 2007Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 7101557Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: February 27, 2003Date of Patent: September 5, 2006Assignee: Board of Regents The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Patent number: 7087723Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: July 1, 2003Date of Patent: August 8, 2006Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 7041635Abstract: The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.Type: GrantFiled: January 28, 2003Date of Patent: May 9, 2006Assignee: IN2GEN Co., Ltd.Inventors: Hun-Taek Kim, In-Young Song, Jae Won Choi, Jin-Wook Jang, Yong-Kook Kim, Ho Soon Lee, Yung-Jue Bang, Dae-Kee Kim
-
Patent number: 7033994Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.Type: GrantFiled: December 21, 2000Date of Patent: April 25, 2006Inventors: Tatsuya Araki, Kazuhiko Tomokiyo, Yasushi Nakatomi, Kaori Teshima, Tomoko Watanabe, Tomohiro Nakagaki
-
Patent number: 7015193Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.Type: GrantFiled: April 19, 2002Date of Patent: March 21, 2006Assignee: University of VermontInventors: Saulius Butenas, Kenneth G. Mann, Kathleen Brummel
-
Patent number: 7005508Abstract: The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and/or hexosamine, with subsituents containing a ONO2 ? group.Type: GrantFiled: August 10, 2001Date of Patent: February 28, 2006Assignee: NicOx S.A.Inventors: Francesca Benedini, Benito Casu, Piero Del Soldato, Paolo Gresele, Annamaria Naggi, Giangiacomo Torri, Simona Venturini
-
Patent number: 6967239Abstract: Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.Type: GrantFiled: December 14, 1998Date of Patent: November 22, 2005Assignee: Laboratoire Francias du Franctionnement et des BiotechnologiesInventors: Abdessatar Chtourou, Michel Nogre, Pierre Porte
-
Patent number: 6956022Abstract: Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.Type: GrantFiled: December 27, 2001Date of Patent: October 18, 2005Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masahiko Tamura, Yasuhiro Oda
-
Patent number: 6953837Abstract: There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex, which particularly contains high-molecular vWF multimers, as well as a factor VIII/vWF-complex obtainable by means of cation exchange chromatography.Type: GrantFiled: November 2, 2001Date of Patent: October 11, 2005Assignee: Baxter AktiengesellschaftInventors: Artur Mitterer, Bernhard Fischer, Öyvind L. Schönberger, Kathrin Thomas-Urban, Friedrich Dorner, Johann Eibl
-
Patent number: 6930087Abstract: A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carriers substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.Type: GrantFiled: December 26, 2002Date of Patent: August 16, 2005Assignee: Opperbas Holding B.V.Inventors: Moshe Baru, Liliana Bar, Israel Nur
-
Patent number: 6903069Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.Type: GrantFiled: October 2, 2001Date of Patent: June 7, 2005Assignee: Novo Nordisk Health Care A/SInventors: Hans Kurt Pingel, Niels Kristian Klausen
-
Patent number: 6884616Abstract: A DNA-construct has been disclosed which is suitable for a tissue-specific expression of a blood coagulation factor like Factor IX, which comprises a DNA coding for an amino acid sequence of a blood coagulation factor and a DNA coding for a promoter which is specific for the expression in hematopoietic cells.Type: GrantFiled: April 27, 2000Date of Patent: April 26, 2005Assignee: ZLB Behring GmbHInventors: Claude Négrier, Marie Héléne Rodriguez, Nathalie Enjolras
-
Patent number: 6855734Abstract: Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation.Type: GrantFiled: August 31, 2001Date of Patent: February 15, 2005Inventor: Jallal Messadek
-
Patent number: 6833352Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.Type: GrantFiled: October 25, 2001Date of Patent: December 21, 2004Assignee: Novo Nordisk Pharmaceuticals, Inc.Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
-
Patent number: 6797260Abstract: A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral “gum” and other “skin” (epithelial) tissues. The composition is preferably in the form of a paste which promotes ease of application and use of the composition. A variety of instruments can be used in application and cleanup of the composition showing versatile unparalleled friendly usage. The composition preferably comprises aluminum chloride, ferric sulfate (subsulfate), regenerated oxidized cellulose, aluminum ammonium sulfate, absorbable gelatin and a solvent. The composition has many dental and medical procedure applications.Type: GrantFiled: September 18, 2003Date of Patent: September 28, 2004Inventor: Terence Prevendar
-
Patent number: 6783774Abstract: There is disclosed a method for stopping bleeding and forming black blood coagulation on contact, comprising administering powdered L-threo-hex-2-enono-1,4-lactone thereof to a bleeding site in an amount of 0.1568 grams for every milliliter of blood. This includes cancer, liver diseases and hemophiliac bleeding in patients or animals in whom the thrombocytopenia or coagulation factors disorders result. Accordingly, the said mechanism of action of powdered L-threo-hex-2-enono-1,4-lactone in the formation of blood coagulation on contact is the unique common pathway for all blood coagulations, which overturns the mechanisms of intrinsic and extrinsic pathways for blood coagulation cascade being the unique pathways for blood coagulation in which the coagulation factors 1, 2, 5, 7, 8, 9, 10 and platelet factor 3 are essential for the pathways.Type: GrantFiled: December 13, 1994Date of Patent: August 31, 2004Inventor: Leslie Binshyang Soong
-
Patent number: 6780614Abstract: A modified Factor VIII cDNA is disclosed wherein the B-domain of the wild type factor cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in two locations of the Factor VIII cDNA and as a promoter a cDNA is used which is suitable for the expression in hematopoietic cell lines and specifically in platelets.Type: GrantFiled: February 8, 2002Date of Patent: August 24, 2004Assignee: Aventis Behring GmbHInventors: Claude Négrier, Jean-Luc Plantier
-
Patent number: 6770744Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: GrantFiled: September 19, 2001Date of Patent: August 3, 2004Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 6652840Abstract: A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral “gum” and other “skin” (epithelial) tissues. The composition is preferably in the form of a paste which promotes ease of application and use of the composition. A variety of instruments can be used in application and cleanup of the composition showing versatile unparalleled friendly usage. The composition preferably comprises aluminum chloride, ferric sulfate (subsulfate), regenerated oxidized cellulose, aluminum ammonium sulfate, absorbable gelatin and a solvent. The composition has many dental and medical procedure applications.Type: GrantFiled: February 8, 2002Date of Patent: November 25, 2003Inventor: Terence Prevendar
-
Patent number: 6593294Abstract: A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carriers substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.Type: GrantFiled: November 22, 2000Date of Patent: July 15, 2003Assignee: Opperbas Holding B.V.Inventors: Moshe Baru, Liliana Bar, Israel Nur
-
Patent number: 6586574Abstract: The invention relates to the use of glycylglycine, optionally in combination with a sugar, and/or a sugar alcohol, and/or an amino acid, as a bulking agent in freeze-drying.Type: GrantFiled: August 15, 2000Date of Patent: July 1, 2003Assignee: NN A/SInventor: Lars Lindgaard Hansen
-
Patent number: 6586573Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: February 22, 2000Date of Patent: July 1, 2003Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 6559133Abstract: A method for treatment of a vascular or cardiovascular condition or acute coronary syndromes comprises administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular condition or acute coronary syndromes. The flavone 8-carboxylic acid is typically flavone 8-acetic acid. The flavone 8-carboxylic acid can be administered alone or in combination with another agent such as a thrombolytic agent, an antithrombotic agent, an anticoagulant, or an antiplatelet agent. The invention also includes pharmaceutical compositions formulated for the treatment of a vascular or cardiovascular condition or acute coronary syndromes.Type: GrantFiled: January 23, 2001Date of Patent: May 6, 2003Inventor: Jozef S. Mruk
-
Patent number: 6521265Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.Type: GrantFiled: June 13, 2000Date of Patent: February 18, 2003Assignee: Biolife, L.L.C.Inventor: James A. Patterson
-
Publication number: 20020177544Abstract: An adenoviral transfer vector for the gene transport of a DNA sequence, which is produced from an adenoviral plasmid which no longer expresses any natural adenoviral proteins and comprisesType: ApplicationFiled: February 19, 1999Publication date: November 28, 2002Applicant: AVENTIS BEHRING GMBHInventors: ANJA HAACK, CHRISTOPH SCHMITT
-
Patent number: 6458563Abstract: The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.Type: GrantFiled: March 10, 2000Date of Patent: October 1, 2002Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 6403556Abstract: A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.Type: GrantFiled: June 17, 1992Date of Patent: June 11, 2002Assignee: Baxter AktiengesellschaftInventors: Johann Eibl, Anton Philapitsch, Hans Peter Schwarz
-
Publication number: 20020065327Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.Type: ApplicationFiled: September 24, 1999Publication date: May 30, 2002Inventors: JIN-AN JIAO, LAWRENCE K. LUEPSCHEN, ESPERANZA L. NIEVES, HING C. WONG, DEAN P. TAYLOR
-
Patent number: 6391343Abstract: The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.Type: GrantFiled: April 10, 1998Date of Patent: May 21, 2002Assignee: Hemosphere, Inc.Inventor: Richard C. K. Yen
-
Patent number: 6346513Abstract: Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occuring Factor VIII. The polypeptides find use in treatment of Hemophilia A.Type: GrantFiled: April 3, 1995Date of Patent: February 12, 2002Assignee: Baxter Trading GmbHInventors: Albert Johannes Joseph Van Ooyen, Hans Pannekoek, Martinus Philippus Verbeet, Robert Willem Van Leen
-
Patent number: 6307032Abstract: There is disclosed a highly purified complex comprising the components factor VIII and vWF having a specific activity of at least 70, preferably 100 to 300 U factor VIII:C/mg, a stable pharmaceutical preparation containing this complex as well as a method of producing the same.Type: GrantFiled: November 18, 1998Date of Patent: October 23, 2001Assignee: Baxter AktiengesellschaftInventors: Wolfgang Schönhofer, Johann Eibl, Alfred Weber, Yendra Linnau
-
Patent number: 6284871Abstract: The present invention relates to biologically active peptides which specifically inhibit the Factor IX-dependent pathway of blood coagulation. These peptides are based on a specific motif which represents a sequence of Factor VIII (amino acid 1811-1818) involved in binding to activated Factor IX as well as to the intact Factor IX zymogen. Binding of said peptides to Factor IX or activated derivatives thereof effectively inhibits complex assembly with Factor VIII. These peptides thereby specifically interfere in the Factor IX-dependent pathway of thrombin formation, while leaving other haemostatic pathways unaffected. By virtue of this unique specificity, the peptides of this invention are particularly useful in novel pharmaceutical compositions for the treatment of thrombotic disorders.Type: GrantFiled: December 9, 1997Date of Patent: September 4, 2001Assignee: Stiching Centraal Laboratorium van de Bloedtransfusiedienst van Nederlandse Rode KruisInventors: Koenraad Mertens, Petrus Johannes Lenting
-
Patent number: 6264988Abstract: The invention provides compositions comprising microspheres of fibrinogen-coated cross-linked albumin microspheres having a size range of primarily from about 100 to about 5000 nanometers diameter, wherein the composition is substantially free microspheres and microsphere aggregates having a diameter of more than 10 micrometers. At least a portion of the fibrinogen on the surface of the microspheres is covalently attached. The particles of the invention are useful for reducing bleeding time when administered to a human or other animal.Type: GrantFiled: June 4, 1998Date of Patent: July 24, 2001Assignee: Hemosphere, Inc.Inventor: Richard C. K. Yen
-
Patent number: 6228613Abstract: There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.Type: GrantFiled: November 6, 1998Date of Patent: May 8, 2001Assignee: Baxter AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Johann Eibl
-
Patent number: 6132729Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.Type: GrantFiled: January 20, 1998Date of Patent: October 17, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Patent number: 6132730Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.Type: GrantFiled: January 20, 1998Date of Patent: October 17, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Patent number: RE39150Abstract: A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.Type: GrantFiled: March 30, 2001Date of Patent: June 27, 2006Assignee: Prohold Technologies, Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: RE42377Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.Type: GrantFiled: July 12, 2007Date of Patent: May 17, 2011Assignees: Stryker Corporation, Stryker NV Operations LimitedInventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox